{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:22Z","timestamp":1791405442017,"version":"4.3.3"},"reference-count":85,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biodefense T32 Training Fellowship","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"Biodefense T32 Training Fellowship","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"Biodefense T32 Training Fellowship","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]},{"name":"Jeane B. Kempner fellowship","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"Jeane B. Kempner fellowship","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"Jeane B. Kempner fellowship","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]},{"name":"Antimicrobial Resistance Training Program at the Texas Medical Center","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"Antimicrobial Resistance Training Program at the Texas Medical Center","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"Antimicrobial Resistance Training Program at the Texas Medical Center","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]},{"name":"NIH","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"NIH","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"NIH","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]},{"name":"UTMB Technology Commercialization Program","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"UTMB Technology Commercialization Program","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"UTMB Technology Commercialization Program","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]},{"name":"John S. Dunn Endowment funding","award":["T32-AI060549"],"award-info":[{"award-number":["T32-AI060549"]}]},{"name":"John S. Dunn Endowment funding","award":["T32-AI179595"],"award-info":[{"award-number":["T32-AI179595"]}]},{"name":"John S. Dunn Endowment funding","award":["R01 AI153524"],"award-info":[{"award-number":["R01 AI153524"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Plague, caused by Yersinia pestis, poses a public health threat not only due to sporadic outbreaks across the globe but also due to its potential as a biothreat agent. Ironically, among the seven deadliest pandemics in global history, three were caused by Y. pestis. Pneumonic plague, the more contagious and severe form of the disease, is difficult to contain, requiring either prophylactic antibiotic treatment or vaccination. However, no vaccine (live attenuated or subunit) is currently approved by the Food and Drug Administration, requiring rigorous preclinical studies in different animal models, thus forming the basis of this study. Objectives: The aim of this study was to evaluate the efficacy and immune responses of two live attenuated vaccines (LAVs), LMA and LMP, either alone or in combination with a trivalent adenoviral vector-based vaccine (Ad5-YFV), in IL-17A-depleted and IgG control mice by using an anti-IL-17A monoclonal antibody (mAb) or its matched isotype IgG, respectively. Methods: IL-17A mAb or IgG isotype control was administered to mice twice per week to their respective groups during the course of immunization. Serum, spleens, and broncho-alveolar lavage fluid (BALF) were collected for assessing immunological responses, and another cohort of mice was intranasally challenged with a lethal dose of parental Y. pestis CO92. Results: Robust humoral and cellular immune responses followed by complete protection were observed in all vaccinated animals against highly lethal intranasal challenge doses of parental Y. pestis CO92. Serum IgG titers to YscF and overall mucosal IgA titers to all three antigens of the Ad5-YFV vaccine were significantly lower, with slightly reduced serum LcrV-neutralizing antibodies when IL-17A was depleted compared to IgG control animals during the course of immunization. A remarkable reduction in Th1 (IFN\u03b3 or IL-2) and Th17 cell populations was observed in IL-17A-depleted mice compared to IgG controls in response to vaccination. On the other hand, B cell activities in germinal centers, overall activated antigen-specific T cells, and memory B and T cells remained at comparable levels in both vaccinated IL-17A-depleted and IgG control mice. Conclusions: These data demonstrated the effectiveness of our vaccines even under the reduced levels of both Th1 and Th17 responses and thus should be suitable for those individuals associated with certain immune deficiencies.<\/jats:p>","DOI":"10.3390\/vaccines12121361","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:58:58Z","timestamp":1733122738000},"page":"1361","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-3841","authenticated-orcid":false,"given":"Emily K.","family":"Hendrix","sequence":"first","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7638-9067","authenticated-orcid":false,"given":"Jian","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Kilgore","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake H.","family":"Neil","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul K.","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5223-3012","authenticated-orcid":false,"given":"Ashok K.","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Center for Biodefense and Emerging Infectious Diseases, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014Etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-024-00958-1","article-title":"Progress on the research and development of plague vaccines with a call to action","volume":"9","author":"Williamson","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.24171\/j.phrp.2021.0288","article-title":"Yersinia pestis antibiotic resistance: A systematic review","volume":"13","author":"Lei","year":"2022","journal-title":"Osong Public Health Res. Perspect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1007\/s00253-021-11389-6","article-title":"Plague vaccines: New developments in an ongoing search","volume":"105","author":"Rosenzweig","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Feodorova, V.A., Lyapina, A.M., Khizhnyakova, M.A., Zaitsev, S.S., Sayapina, L.V., Arseneva, T.E., Trukhachev, A.L., Lebedeva, S.A., Telepnev, M.V., and Ulianova, O.V. (2018). Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine. PLoS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006511"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cote, C.K., Biryukov, S.S., Klimko, C.P., Shoe, J.L., Hunter, M., Rosario-Acevedo, R., Fetterer, D.P., Moody, K.L., Meyer, J.R., and Rill, N.O. (2021). Protection elicited by attenuated live Yersinia pestis vaccine strains against lethal infection with virulent Y. pestis. Vaccines, 9.","DOI":"10.3390\/vaccines9020161"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/CVI.00499-15","article-title":"Intramuscular immunization of mice with a live-Attenuated triple mutant of yersinia pestis co92 induces robust humoral and cell-mediated immunity to completely protect animals against pneumonic plague","volume":"22","author":"Tiner","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/npjvaccines.2016.20","article-title":"Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague","volume":"1","author":"Tiner","year":"2016","journal-title":"NPJ Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-020-00275-3","article-title":"A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform","volume":"6","author":"Kilgore","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/CVI.00150-16","article-title":"A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates","volume":"23","author":"Sha","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01926-18","DOI":"10.1128\/mBio.01926-18","article-title":"A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague","volume":"9","author":"Tao","year":"2018","journal-title":"mBio"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.vaccine.2016.03.094","article-title":"Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague","volume":"34","author":"Sanapala","year":"2016","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.vaccine.2004.01.007","article-title":"A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice","volume":"22","author":"Morton","year":"2004","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Biryukov, S., Dankmeyer, J.L., Shamsuddin, Z., Velez, I., Rill, N.O., Rosario-Acevedo, R., Klimko, C.P., Shoe, J.L., Hunter, M., and Ward, M.D. (2021). Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.726416"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular Fl-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1574-695X.2012.00974.x","article-title":"Immunogenicity and efficacy of an anthrax\/plague DNA fusion vaccine in a mouse model","volume":"65","author":"Albrecht","year":"2012","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Shattock, R.J., Andrianaivoarimanana, V., McKay, P.F., Randriantseheno, L.N., Murugaiah, V., Samnuan, K., Rogers, P., Tregoning, J.S., Rajerison, M., and Moore, K.M. (2023). A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1247041"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eadg1036","DOI":"10.1126\/sciadv.adg1036","article-title":"A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium","volume":"9","author":"Kon","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2012.34","article-title":"Plague vaccines: Current developments and future perspectives","volume":"1","author":"Feodorova","year":"2012","journal-title":"Emerg. Microbes Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-019-0105-9","article-title":"Plague vaccine: Recent progress and prospects","volume":"4","author":"Sun","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_21","unstructured":"DynPort Vaccine Company Llc, A.G.C (2023, September 29). Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00097396?term=Safety,%20Tolerability%20%26%20Immunogenicity%20of%20the%20Recombinant%20Plague%20Vaccine%20rF1V&rank=1."},{"key":"ref_22","unstructured":"DynPort Vaccine Company Llc, A.G.C (2023, September 29). Recombinant Plague Vaccine rF1V in Healthy Volunteers, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00332956?term=Recombinant%20Plague%20Vaccine%20rF1V%20in%20Healthy%20Volunteers.%20&rank=1."},{"key":"ref_23","unstructured":"DynPort Vaccine Company Llc, A.G.C (2023, September 29). Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01122784?term=Randomized%20Single-Blinded%20Study%20to%20Evaluate%20Safety%20and%20Immunogenicity%20of%20Recombinant%20Plague%20Vaccine%20With%20and%20Without%20Adjuvant.%20&rank=1."},{"key":"ref_24","unstructured":"PharmAthene, U.K.L. (2023, September 29). One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens), ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00246467?term=One%20Year%20Study%20to%20Evaluate%20Three%20Different%20Adjuvanted%20Doses%20of%20the%20Recombinant%20Plague%20Vaccine%20&rank=1."},{"key":"ref_25","unstructured":"Diseases, N.I.o.A.a.I (2023, September 29). Dose Escalation Trial of a Plague Vaccine, Flagellin\/F1\/V, in Healthy Adult Volunteers, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01381744?term=.%20Dose%20Escalation%20Trial%20of%20a%20Plague%20Vaccine,%20Flagellin%2FF1%2FV,%20in%20Healthy%20Adult%20Volunteers.%20&rank=1."},{"key":"ref_26","unstructured":"Jiangsu Province Centers for Disease Control and, P. (2023, September 29). Immunogenicity and Safety of Subunit Plague Vaccine, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02596308?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Plague%20Vaccine&rank=1."},{"key":"ref_27","unstructured":"Jiangsu Province Centers for Disease Control and, P (2023, September 29). Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05330624?term=.%20Immunogenicity%20and%20Safety%20of%20Subunit%20Vaccine%20of%20Plague%20Vaccine%20With%20Two%20Immunization%20Regimens&rank=1."},{"key":"ref_28","unstructured":"OV Group (2021). Investigating a Vaccine Against Plague (PlaVac), Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)."},{"key":"ref_29","unstructured":"Dynavax Technologies, C. (2023, September 29). Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018\u00ae Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age, ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05506969?term=Trial%20of%20the%20Immunogenicity,%20Safety,%20and%20Tolerability%20of%20rF1V%20Vaccine%20With%20CpG%201018%20Adjuvant%20Compared%20With%20rF1V%20Vaccine&rank=1."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JCM.00064-11","article-title":"Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks","volume":"49","author":"Sha","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_31","unstructured":"Meka-Mechenko, T.V. (1967). F1-negative natural Y. pestis Strains. Advances in Experimental Medicine and Biology, Springer."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/IAI.02778-14","article-title":"Combinational deletion of three membrane protein-encoding genes highly attenuates Yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague","volume":"83","author":"Tiner","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.micpath.2012.09.011","article-title":"A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague","volume":"55","author":"Sha","year":"2013","journal-title":"Microb. Pathog."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.micpath.2015.02.005","article-title":"Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages","volume":"80","author":"Tiner","year":"2015","journal-title":"Microb. Pathog."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Matson, J.S., Durick, K.A., Bradley, D.S., and Nilles, M.L. (2005). Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol., 5.","DOI":"10.1186\/1471-2180-5-38"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pep.2005.02.016","article-title":"Yersinia pestis Yop secretion protein F: Purification, characterization, and protective efficacy against bubonic plague","volume":"42","author":"Swietnicki","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.1137195","article-title":"A plasminogen-activating protease specifically controls the development of primary pneumonic plague","volume":"315","author":"Lathem","year":"2007","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4049\/jimmunol.1301687","article-title":"IL-17A Produced by Neutrophils Protects against Pneumonic Plague through Orchestrating IFN-\u03b3\u2013Activated Macrophage Programming","volume":"192","author":"Bi","year":"2014","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.1003303","article-title":"IL-17 Contributes to Cell-Mediated Defense against Pulmonary Yersinia pestis Infection","volume":"186","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e03223-21","DOI":"10.1128\/mBio.03223-21","article-title":"Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague","volume":"12","author":"Kilgore","year":"2021","journal-title":"mBio"},{"key":"ref_41","unstructured":"ThermoScientific (2024, November 27). Instructions EZ-Link Sulfo-NHS-Biotin. Available online: https:\/\/assets.thermofisher.com\/TFS-Assets\/LSG\/manuals\/MAN0016134_2161850_EZLinkSulfoNHS_Biotin_UG.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb. Pathog."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/IAI.01529-07","article-title":"Braun lipoprotein (Lpp) contributes to virulence of yersiniae: Potential role of Lpp in inducing bubonic and pneumonic plague","volume":"76","author":"Sha","year":"2008","journal-title":"Infect. Immun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ltab020","DOI":"10.1093\/immadv\/ltab020","article-title":"Potential human immunotherapeutics for plague","volume":"1","author":"Andrianaivoarimanana","year":"2021","journal-title":"Immunother. Adv."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bowyer, G., Rampling, T., Powlson, J., Morter, R., Wright, D., Hill, A.V.S., and Ewer, K.J. (2018). Activation-induce markers detect vaccine-specific CD4+ T cell responses not measured by assays conventionally used in clinical trials. Vaccines, 6.","DOI":"10.3390\/vaccines6030050"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/imm.12929","article-title":"The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination","volume":"154","author":"Gray","year":"2018","journal-title":"Immunology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3360310","DOI":"10.1155\/2023\/3360310","article-title":"IL-17: Balancing Protective Immunity and Pathogenesis","volume":"2023","author":"Sun","year":"2023","journal-title":"J. Immunol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: From bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"ra8","DOI":"10.1126\/scisignal.2000066","article-title":"IL-17 receptor signaling inhibits C\/EBPbeta by sequential phosphorylation of the regulatory 2 domain","volume":"2","author":"Shen","year":"2009","journal-title":"Sci. Signal"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Navarro-Comp\u00e1n, V., Puig, L., Vidal, S., Ram\u00edrez, J., Llamas-Velasco, M., Fern\u00e1ndez-Carballido, C., Almod\u00f3var, R., Pinto, J.A., Gal\u00edndez-Aguirregoikoa, E., and Zarco, P. (2023). The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1332177"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00281-009-0191-2","article-title":"Th17 cytokines and vaccine-induced immunity","volume":"32","author":"Lin","year":"2010","journal-title":"Semin. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mi.2009.100","article-title":"Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa","volume":"2","author":"Khader","year":"2009","journal-title":"Mucosal Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2005.12.066","article-title":"Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv","volume":"24","author":"Romano","year":"2006","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"Dougados","year":"2018","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0968-0004(03)00067-7","article-title":"The STIR-domain superfamily in signal transduction, development and immunity","volume":"28","author":"Novatchkova","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ni.3489","article-title":"Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis","volume":"17","author":"Klose","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.AID-0019-2014","article-title":"Functions of Antibodies","volume":"2","author":"Forthal","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/IAI.00806-09","article-title":"Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines","volume":"78","author":"Llosa","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1128\/IAI.00398-10","article-title":"Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility","volume":"78","author":"Bishop","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acsinfecdis.0c00842","article-title":"Recombinant Human Secretory IgA Induces Salmonella Typhimurium Agglutination and Limits Bacterial Invasion into Gut-Associated Lymphoid Tissues","volume":"7","author":"Richards","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zheng, B., Lu, J., Wu, H., Zhang, Q., Jiao, L., Pan, H., and Zhou, J. (2024). Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.01054-24"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Velappan, N., Biryukov, S.S., Rill, N.O., Klimko, C.P., Rosario-Acevedo, R., Shoe, J.L., Hunter, M., Dankmeyer, J.L., Fetterer, D.P., and Bedinger, D. (2024). Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0305034"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.4049\/jimmunol.178.6.3786","article-title":"IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection","volume":"178","author":"Umemura","year":"2007","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2009.08.025","article-title":"Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis","volume":"31","author":"Lin","year":"2009","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coi.2009.05.021","article-title":"Developmental plasticity of Th17 and Treg cells","volume":"21","author":"Lee","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.4049\/jimmunol.1002860","article-title":"Sensitivity and resistance to regulation by IL-4 during Th17 maturation","volume":"187","author":"Cooney","year":"2011","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.immuni.2021.06.018","article-title":"COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge","volume":"54","author":"DiPiazza","year":"2021","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gopal, R., Monin, L., Slight, S., Uche, U., Blanchard, E., Fallert Junecko, B.A., Ramos-Payan, R., Stallings, C.L., Reinhart, T.A., and Kolls, J.K. (2014). Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004099"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41385-021-00407-5","article-title":"IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F","volume":"14","author":"Borkner","year":"2021","journal-title":"Mucosal Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2019.07.103","article-title":"Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague","volume":"37","author":"Bowen","year":"2019","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Davies, M.L., Biryukov, S.S., Rill, N.O., Klimko, C.P., Hunter, M., Dankmeyer, J.L., Miller, J.A., Shoe, J.L., Mlynek, K.D., and Talyansky, Y. (2024). Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1397579"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kilgore, P.B., Sha, J., Hendrix, E.K., Neil, B.H., Lawrence, W.S., Peel, J.E., Hittle, L., Woolston, J., Sulakvelidze, A., and Schwartz, J.A. (2024). A bacteriophage cocktail targeting Yersinia pestis provides strong post-exposure protection in a rat pneumonic plague model. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.00942-24"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2008.12.019","article-title":"Properties and origin of human Th17 cells","volume":"47","author":"Romagnani","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: Interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/COH.0b013e32833647c2","article-title":"Human and murine Th17","volume":"5","author":"Annunziato","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/02770903.2015.1044251","article-title":"IL-17 polymorphisms and asthma risk: A meta-analysis of 11 single nucleotide polymorphisms","volume":"52","author":"Jin","year":"2015","journal-title":"J. Asthma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"128490","DOI":"10.1155\/2014\/128490","article-title":"Interleukin-17 gene polymorphisms contribute to cancer risk","volume":"2014","author":"Niu","year":"2014","journal-title":"Mediat. Inflamm."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1361\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:44:20Z","timestamp":1760114660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":85,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["vaccines12121361"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12121361","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}